Intravenous immunoglobulin therapy for rheumatic diseases

Area of Science:

• Rheumatology
• Immunology
• Autoimmune Diseases

Background:

• Intravenous immunoglobulins (IVIg) are effective for idiopathic thrombocytopenic purpura and Kawasaki disease.
• Anecdotal evidence suggests potential benefits of IVIg in various rheumatic and connective tissue diseases.
• The immunomodulatory properties of IVIg, including idiotypic antibodies, are recognized.

Purpose of the Study:

• To review the current evidence for IVIg efficacy in rheumatic and connective tissue diseases.
• To explore the potential of IVIg as a treatment for autoimmune conditions.

Main Methods:

• Review of anecdotal and open-label studies on IVIg in specific rheumatic and connective tissue diseases.
• Analysis of the immunomodulatory mechanisms of IVIg.

Main Results:

• Open studies have shown occasional impressive clinical and biologic results with good tolerance for IVIg in conditions such as rheumatoid arthritis, juvenile rheumatoid arthritis, Still's disease, systemic lupus erythematosus, dermatomyositis-polymyositis, and vasculitis.
• IVIg contains antibodies targeting pathogenic autoantibodies, suggesting an immunomodulatory role.

Conclusions:

• The efficacy of IVIg in rheumatic and connective tissue diseases requires confirmation through double-blind placebo-controlled studies.
• IVIg represents a potential source of immunomodulating antibodies for treating autoimmune diseases.